"uuid:ID","rationale","versionIdentifier","instanceType","id"
"8467a7dc-d259-4b1b-92aa-5c58d86bfcee","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion","StudyVersion_1"
